Cancer drug access extended: pfizer study offers continued palbociclib to eligible patients

NCT ID NCT05226871

Ongoing Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provides continued access to the cancer drug palbociclib (IBRANCE) for up to 35 patients with breast or head and neck cancer who have already benefited from it in earlier Pfizer trials. Participants will keep taking their current treatment combination, which may include cetuximab, fulvestrant, or letrozole. The main goal is to monitor long-term safety by tracking serious side effects and any reasons for stopping treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Palbociclib (IBRANCE) combined with cetuximab, fulvestrant, or letrozole
What this could lead to: If successful, this study could show that long-term use of palbociclib is safe for patients with breast or head and neck cancer who have already benefited from it.
What could go wrong: This is a small, non-randomized study with only 35 participants, so results may not apply to everyone. It focuses on safety, not on proving the drug works better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm head and neck cancer Head and Neck Neoplasms Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER HEAD AND NECK CANCER

Contacts and locations

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Science

Beijing, 100021, China
Department of Medicine, Faculty of Medicine Siriraj Hospital

Bangkok, 10700, Thailand
Faculty of Medicine, Ramathibodi Hospital, Mahidol University

Ratchathewi, Bangkok, 10400, Thailand
Harbin Medical University Cancer Hospital

Harbin, Heilongjiang, 150081, China
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

Monterrey, Nuevo León, 64460, Mexico
Hubei Cancer Hospital

Wuhan, Hubei, 430079, China
Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, 110042, China
Mackay Memorial Hospital

Taipei, 10449, Taiwan
Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council

Dnipro, 49102, Ukraine
Municipal non-profit enterprise Regional Clinical Hospital of Ivano-Frankivsk Regional Council

Ivano-Frankivsk, 76000, Ukraine
National Cancer Center

Goyang-si, Gyeonggi-do, 10408, South Korea
National Cheng Kung University Hospital

Tainan, 704302, Taiwan
Regional Municipal Non-profit Enterprise "Bukovinian Clinical Oncology Center"

Chernivtsi, Chernivetska Oblast, 58013, Ukraine
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

Shanghai, Shanghai Municipality, 200025, China
Samsung Medical Center

Seoul, Seoul-teukbyeolsi [seoul], 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Sun Yat-sen Memorial Hospital of Sun Yat-sen University

Guangzhou, Guangdong, 510000, China
The First Affiliated Hospital of Anhui Medical University

Hefei, Anhui, 230022, China
The First Hospital of China Medical University

Shenyang, Liaoning, 110167, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
UCSF Medical Center at Mission Bay

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.